NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Company Overview - NeuroSense Therapeutics Ltd. is a late-clinical stage biotechnology company focused on developing novel treatments for severe neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) [5] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options available [5] Alzheimer's Disease Insights - Alzheimer's disease is a progressive neurodegenerative disorder affecting over 30 million people globally, characterized by memory loss, cognitive decline, and behavioral changes, with no current cure available [3] - Existing therapies provide only limited symptomatic relief, highlighting the need for disease-modifying treatments that can slow or halt disease progression [3] PrimeC Drug Candidate - PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining two FDA-approved drugs: ciprofloxacin and celecoxib [4] - The drug is designed to target multiple mechanisms contributing to neuron degeneration, inflammation, iron accumulation, and impaired RNA regulation, potentially inhibiting the progression of ALS and AD [4] Clinical Study Results - The safety analysis from the Phase 2 NST-AD-001 study of PrimeC in Alzheimer's disease indicated a favorable tolerability profile, with no serious adverse events or new safety signals reported [2] - Clinical outcome measures from the study are descriptive by design, and results, including biomarker data, are expected to be reported in Q1 2026 [1][2]